NJ State Employees Deferred Compensation Plan’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-17,500	Closed	-$264K	–	389
2016 Q4	$264K	Hold	17,500	–	–	0.05%	327
2016 Q3	$267K	Hold	17,500	–	–	0.06%	320
2016 Q2	$679K	Hold	17,500	–	–	0.14%	224
2016 Q1	$603K	Hold	17,500	–	–	0.13%	244
2015 Q4	$941K	Hold	17,500	–	–	0.19%	176
2015 Q3	$701K	Buy	+17,500	New	+$571K	0.15%	219

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's ITCI Position: Q1 2017 in Review

NJ State Employees Deferred Compensation Plan sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2017, closing a stake of 17,500 shares — an estimated $264K sold.

NJ State Employees Deferred Compensation Plan first reported a position in ITCI in Q3 2015 and held it in 6 quarters. The position peaked at $941K in Q4 2015. 117 funds tracked by Wall St. Rank hold ITCI as of Q1 2017.

NJ State Employees Deferred Compensation Plan reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2017 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 17,500 Intra-Cellular Therapies Inc. shares in Q1 2017, an estimated $264K.
NJ State Employees Deferred Compensation Plan first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 6 quarters.
NJ State Employees Deferred Compensation Plan's Intra-Cellular Therapies Inc. position peaked at $941K in Q4 2015.
117 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2017.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q1 2017, filed 27 Apr 2017.